BackQuest Diagnostics Overview
Quest Diagnostics, Inc.

Quest Diagnostics Target Price

Analysts' average 12-month price target for Quest Diagnostics is $250.

Get informed when a big investor buys or sells

+ Follow

Share Price

$239.4

Average Target Price

$246.332.9% upside

6 analysts in the last 4 months

High: $260 | Low: $232

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-29Argus Research$2608.6% upsideOpen
2026-07-24UBSKevin Caliendo$2323.1% downsideOpen
2026-07-24Robert W. Baird$2556.5% upsideOpen
2026-07-23Barclays$2504.4% upsideOpen
2026-07-23Jefferies$2452.3% upsideOpen
2026-07-13Robert W. Baird$2361.4% downsideOpen
2026-04-21Evercore ISI$2256% downsideOpen
2026-04-21Jefferies$2256% downsideOpen
2026-04-08Evercore ISI$21012.3% downsideOpen
2026-02-12Mizuho Securities$2351.8% downsideOpen
2026-02-11UBS$21012.3% downsideOpen
2026-02-11Truist Financial$2208.1% downsideOpen
2026-02-11Evercore ISIElizabeth Anderson$2208.1% downsideOpen
2026-02-11Robert W. Baird$2198.5% downsideOpen
2026-02-10JefferiesTycho Peterson$2208.1% downsideOpen
2026-01-30Barclays$21012.3% downsideOpen
2025-10-27Piper Sandler$20016.5% downsideOpen
2025-10-22Truist Financial$20514.4% downsideOpen
2025-10-22Morgan StanleyErin Wright$20713.5% downsideOpen
2025-10-22Barclays$19518.5% downsideOpen
2025-10-21Jefferies$21510.2% downsideOpen
2025-10-21Leerink Partners$21012.3% downsideOpen
2025-10-17UBSKevin Caliendo$19020.6% downsideOpen
2025-10-17Mizuho Securities$21012.3% downsideOpen
2025-10-14Truist Financial$19518.5% downsideOpen
2025-10-08Evercore ISI$19020.6% downsideOpen
2025-10-02Barclays$19020.6% downsideOpen
2025-08-25Robert W. Baird$19419% downsideOpen
2025-07-23Evercore ISIElizabeth Anderson$18522.7% downsideOpen
2025-04-02Redburn PartnersJamie Clark$19518.5% downsideOpen
2025-02-03Piper SandlerDavid Westenberg$18024.8% downsideOpen
2025-01-31Truist FinancialDavid MacDonald$18224% downsideOpen
2025-01-31Robert W. BairdEric Coldwell$18921.1% downsideOpen
2024-10-23CitigroupPatrick Donnelly$18522.7% downsideOpen
2024-10-23Leerink PartnersMichael Cherny$16531.1% downsideOpen
2024-10-23BarclaysStephanie Davis$16829.8% downsideOpen
2024-10-23Robert W. BairdEric Coldwell$18224% downsideOpen
2024-10-22CFRAPaige Meyer$17825.6% downsideOpen
2024-10-07Truist FinancialDavid MacDonald$16531.1% downsideOpen
2024-07-29Mizuho SecuritiesAnn Hynes$16033.2% downsideOpen
2024-07-24Robert W. BairdEric Coldwell$15435.7% downsideOpen
2024-07-15Truist FinancialDavid MacDonald$15834% downsideOpen
2024-04-25BarclaysStephanie Davis$14439.8% downsideOpen
2024-02-07JefferiesBrian Tanquilut$15535.3% downsideOpen
2023-02-03Wells Fargo$14041.5% downsideOpen
2023-01-06Morgan Stanley$15834% downsideOpen
2022-11-17Citigroup$12547.8% downsideOpen
2022-05-03Morgan Stanley$14240.7% downsideOpen
2022-04-25Wells Fargo$15037.3% downsideOpen
2022-04-09CitigroupRalph Giacobbe$17526.9% downsideOpen

Quest Diagnostics (DGX) FAQ

Quest Diagnostics posts a target price of $250. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $250 for DGX means covering analysts, on average, see the stock 2.9% upside of $239.4 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for DGX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Quest Diagnostics's other metric pages and overview cover the third.

Judging Quest Diagnostics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $250 here, then scan peer and history charts to see if the gap is persistent.